Liverpool COVID-19 Interactions (original) (raw)
If a drug is not listed below it cannot automatically be assumed it is safe to coadminister.
COVID Drugs
Selected Drugs will be displayed here.
Drug Class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}Drug Class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}- Drug Class: {{drug.drug_class_name || 'Not Available'}}
- Drug Class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}
- Drug Class: {{drug.drug_class_name || 'Not Available'}}
Co-medications
Selected Co-medications will be displayed here
Drug class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}Drug class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}- Drug Class: {{drug.drug_class_name || 'Not Available'}}
- Drug Class: {{drug.drug_class_name || 'Not Available'}}
Trade Name: {{vm.getTradeNames(drug)}}
- Drug Class: {{drug.drug_class_name || 'Not Available'}}
Check COVID/COVID drug interactions
Drug Interactions will be displayed here
Drug combinations may have been assessed either by study or within the product label, or an interaction may have been predicted based on the metabolic profiles of the drugs.
These drugs should not be coadministered
Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration.
Potential interaction likely to be of weak intensity. Additonal action/monitoring or dosage adjustment is unlikely to be required
No clinically significant interaction expected
Potential Weak Interaction
Drug combinations may have been assessed either by study or within the product label, or an interaction may have been predicted based on the metabolic profiles of the drugs.
These drugs should not be coadministered
Potential clinically significant interaction that is likely to require additional monitoring, alteration of drug dosage or timing of administration.
Potential interaction likely to be of weak intensity. Additonal action/monitoring or dosage adjustment is unlikely to be required
No clinically significant interaction expected
| {{col.name}} | | | ------------ | | | {{row.name}} | |